Insider Monkey41d agoneutral
Is Johnson & Johnson (JNJ) Building a Stronger Post-Stelara Growth Story?Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
109last 24h
3129last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Insider Monkey42d agoneutral
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?24/7 Wall St.43d agoneutral
Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major DownturnsSimply Wall St.43d agoneutral
What Does Johnson & Johnson (JNJ) New Clinical Data Mean For Its Stock?Motley Fool44d agobullish
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?24/7 Wall St.44d agoneutral
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade24/7 Wall St.44d agoneutral
The 1 Number That Decides Whether a Dividend Lasts Your Whole RetirementProactive44d agoneutral
Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis studyPharma Voice44d agoneutral
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalryInsider Monkey45d agoneutral
J&J’s RYBREVANT Shows Strong Survival. Is J&J’s Oncology Franchise Gaining?Insider Monkey45d agobearish
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?Insider Monkey45d agoneutral
Apollo’s Johnson & Johnson Deal Could Open a New Healthcare Growth Avenue24/7 Wall St.45d agoneutral
CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More